A Phase 2 interventional study of ABX464 in Ulcerative Colitis, sponsored by Abivax S.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-29.
Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Colitis, Ulcerative with a site in Belgium — 26 open to participants now, 50 under way, 27 of them phase 3. Colitis, Ulcerative · Belgium.
Among the 187 studies in Colitis, Ulcerative with a site in Belgium, this one is the 163rd largest by enrollment of the 168 interventional ones that give a count, is one of 17 that started in 2018, is one of 59 in phase 2, and was the 98th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →26 of the 187 studies in Colitis, Ulcerative with a site in Belgium are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Belgium, United States, Germany and 2 more countries
Ages 18–60
Janssen Research & Development, LLC · Sites in Belgium, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Imelda GI Clinical Research Center · Sites in Belgium
Ages 16+
Sanofi · Sites in Belgium, United States, Argentina and 28 more countries
Ages 16–80
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 71 · Phase 3 82 · Phase 4 11
First in 2003; this study’s year is marked. 17 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 198 across the 168 interventional studies, 280 across the 19 observational. Of the 134 that completed or were terminated, 80 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
160 of 187 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 8 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
12 of the studies in Colitis, Ulcerative with a site in Belgium that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
Add all 12 to your calendar (.ics) → With an account.
Among the 187 studies in Colitis, Ulcerative with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-101 clinical study (induction study) and who are willing to continue their treatment.
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-101 clinical study (induction study) and who are willing to continue their treatment.
All subjects will receive ABX464 given at 50 mg o.d irrespective of their previous treatment received in the ABX464-101 study (i.e. ABX464 or Placebo).
The actual treatment received by a subject throughout the previous study (ABX464-101) will not be known at the time the subjects enter this follow-up study. This treatment group will be communicated (throughout the investigators) to the subjects at the end of the ABX464-101 study (planned in Q3/2018).
The enrolment in this follow-up study will be based on the willingness of the subject to carry on his/her participation and also based on investigator's judgement.
Subjects will be treated with ABX464 for an overall period of 48 months. Subjects will be followed up weekly during the first month, every two weeks during the second month and then on a monthly basis until M24, then quaterly from M24 to M48.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject will be eligible for inclusion in this study only if ALL of the following criteria apply:
Subjects with hematological and biochemical laboratory parameters as follows at the D56 visit of the ABX464-101 study:
Exclusion Criteria:
The following criterion should be checked at the time of screening. If this exclusion criterion applies, the subject will not be included in the study:
▪ Any condition, which in the opinion of the investigator, could compromise the subject's safety or the adherence to the study protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive ABX464 at 50 mg o.d for an overall period of 48 months.
Drug: ABX464
All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.
Number of Treatment-emergent Adverse Events
Number of treatment-emergent adverse events in ABX464 treated subjects
Time frame: Through subject study treatment, up to 48 months
Total Mayo Score
The change from Day 0 up to Month 48 in Total Mayo Score. total mayo score is an index and consists of 4 items: stool frequency, rectal bleeding, flexible sigmoidoscopic examination, and a physician global assessment of disease activity. Each parameter of the score ranges from zero (normal or inactive disease) to 3 (severe activity). The total mayo score scale ranging is from 0 to 12 The change from baseline of this score is part of the clinical response definition: to get a clinical response, a reduction in Total Mayo score of at least 2 points is required. A higher (in negative) change shows a better clinical response.
Time frame: Up to Month 48
Partial Mayo Score
The change from Day 0 up to Month 48 in Partial Mayo Score; Partial Mayo score is an index and consists of 3 items: stool frequency, rectal bleeding and a physician global assessment of disease activity. Each parameter of the score ranges from zero (normal or inactive disease) to 3 (severe activity). The partial mayo score scale ranging is from 0 to 9. A higher (in negative) change from baseline shows a better clinical response
Time frame: Up to Month 48
Number of Subjects With Clinical Response at Month 48
Clinical response was defined as: reduction in Total Mayo Score (TMS) of at least 2 points and \>= 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of \>= 1 point or absolute rectal bleeding sub-score of \<= 1 point.
Time frame: up to 48 months
Number of Subjects With Clinical Remission at Month 48
Clinical remission was achieved when all the following criteria were met in the components of the Mayo clinical Score: rectal bleeding sub-score = 0 central endoscopy sub-score \<= 1 stool frequency sub-score \<= 1
Time frame: up to 48 months
Number of Subject With Endoscopic Improvement at Month 48
oEndoscopic improvement was achieved if the Mayo central endoscopic sub-score is 0 or 1.
Time frame: up to 48 Months
Number of Subjects With Endoscopic Remission at Month 48
Endoscopic remission was defined as Mayo central endoscopic sub-score = 0
Time frame: up to 48 months
Fecal Calprotectin
The change from Day 0 up to Month 48 in fecal calprotectin A higher (in negative) change shows a better efficacy
Time frame: Up to Month 48
CRP Levels
The change from Day 0 up to Month 48 in CRP levels
Time frame: Up to Month 48
Number of Treatment-emergent Serious Adverse Events
The number of incidences of treatment-emergent serious adverse events
Time frame: Through subject study treatment, up to 48 months
Number of Treatment-emergent Adverse Events of Special Interest
The number of incidences of treatment-emergent adverse events of special interest
Time frame: Through subject study treatment, up to 48 months
Number of Adverse Events Leading to Investigational Product Discontinuation
The number of incidences of adverse events leading to investigational product discontinuation
Time frame: Through subject study treatment, up to 48 months
Number of Specific Laboratory Abnormalities
The number of incidences of specific laboratory abnormalities
Time frame: Through first year of subject study treatment, 12 months
SF-36 Quality of Life Questionnaire (SF-36 Physical Component)
Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health on eight multi-item dimensions, covering functional status, well-being, and overall evaluation of health. These items are grouped in 2 distincts components: a physical component (SF-36 physical) and a mental component (SF-36 mental). This outcome describes the SF-36 physical component. Each item score ranging is from 0 to 100. A higher positive value in change indicate a better health status. The higher the change from baseline, the better improvement
Time frame: Up to 24 months
SF-36 Quality of Life Questionnaire (SF-36 Mental Component)
Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health on eight multi-item dimensions, covering functional status, well-being, and overall evaluation of health. These items are grouped in 2 distincts components: a physical component (SF-36 physical) and a mental component (SF-36 mental). This outcome describes the SF-36 mental component. Each item score ranging is from 0 to 100. A higher positive value in change indicate a better health status. The higher the change from baseline, the better improvement
Time frame: Up to 24 months
Erythrocyte Sedimentation Rate (ESR) Levels
The change from Day 0 up to Month 48 in ESR levels
Time frame: up to 48 Months
| Milestone | ABX464 Treatment Arm |
|---|---|
| Started | 22 |
| Completed | 11 |
| Not completed | 11 |
Number of treatment-emergent adverse events in ABX464 treated subjects
| events | ABX464 Treatment Arm |
|---|---|
| Number of Treatment-emergent Adverse Events | 145 |
The change from Day 0 up to Month 48 in Total Mayo Score. total mayo score is an index and consists of 4 items: stool frequency, rectal bleeding, flexible sigmoidoscopic examination, and a physician global assessment of disease activity. Each parameter of the score ranges from zero (normal or inactive disease) to 3 (severe activity). The total mayo score scale ranging is from 0 to 12 The change from baseline of this score is part of the clinical response definition: to get a clinical response, a reduction in Total Mayo score of at least 2 points is required. A higher (in negative) change shows a better clinical response.
| units on a scale | ABX464 Treatment Arm |
|---|---|
| Total Mayo Score | -3.0 ± 3.4 |
The change from Day 0 up to Month 48 in Partial Mayo Score; Partial Mayo score is an index and consists of 3 items: stool frequency, rectal bleeding and a physician global assessment of disease activity. Each parameter of the score ranges from zero (normal or inactive disease) to 3 (severe activity). The partial mayo score scale ranging is from 0 to 9. A higher (in negative) change from baseline shows a better clinical response
| units on a scale | ABX464 Treatment Arm |
|---|---|
| Partial Mayo Score | -2.2 ± 2.4 |
Clinical response was defined as: reduction in Total Mayo Score (TMS) of at least 2 points and \>= 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of \>= 1 point or absolute rectal bleeding sub-score of \<= 1 point.
| Participants | ABX464 Treatment Arm |
|---|---|
| Number of Subjects With Clinical Response at Month 48 | 11 |
Clinical remission was achieved when all the following criteria were met in the components of the Mayo clinical Score: rectal bleeding sub-score = 0 central endoscopy sub-score \<= 1 stool frequency sub-score \<= 1
| Participants | ABX464 Treatment Arm |
|---|---|
| Number of Subjects With Clinical Remission at Month 48 | 9 |
oEndoscopic improvement was achieved if the Mayo central endoscopic sub-score is 0 or 1.
| Participants | ABX464 Treatment Arm |
|---|---|
| Number of Subject With Endoscopic Improvement at Month 48 | 9 |
Endoscopic remission was defined as Mayo central endoscopic sub-score = 0
| Participants | ABX464 Treatment Arm |
|---|---|
| Number of Subjects With Endoscopic Remission at Month 48 | 6 |
The change from Day 0 up to Month 48 in fecal calprotectin A higher (in negative) change shows a better efficacy
| ug/g | ABX464 Treatment Arm |
|---|---|
| Fecal Calprotectin | -299.69 ± 472.28 |
The change from Day 0 up to Month 48 in CRP levels
| mg/L | ABX464 Treatment Arm |
|---|---|
| CRP Levels | 2.29 ± 4.82 |
The number of incidences of treatment-emergent serious adverse events
| events | ABX464 Treatment Arm |
|---|---|
| Number of Treatment-emergent Serious Adverse Events | 3 |
The number of incidences of treatment-emergent adverse events of special interest
| events | ABX464 Treatment Arm |
|---|---|
| Number of Treatment-emergent Adverse Events of Special Interest | 15 |
The number of incidences of adverse events leading to investigational product discontinuation
| event | ABX464 Treatment Arm |
|---|---|
| Number of Adverse Events Leading to Investigational Product Discontinuation | 1 |
The number of incidences of specific laboratory abnormalities
| events | ABX464 Treatment Arm |
|---|---|
| Number of Specific Laboratory Abnormalities | 17 |
Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health on eight multi-item dimensions, covering functional status, well-being, and overall evaluation of health. These items are grouped in 2 distincts components: a physical component (SF-36 physical) and a mental component (SF-36 mental). This outcome describes the SF-36 physical component. Each item score ranging is from 0 to 100. A higher positive value in change indicate a better health status. The higher the change from baseline, the better improvement
| units on a scale | ABX464 Treatment Arm |
|---|---|
| SF-36 Quality of Life Questionnaire (SF-36 Physical Component) | 4.82 ± 4.23 |
Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health on eight multi-item dimensions, covering functional status, well-being, and overall evaluation of health. These items are grouped in 2 distincts components: a physical component (SF-36 physical) and a mental component (SF-36 mental). This outcome describes the SF-36 mental component. Each item score ranging is from 0 to 100. A higher positive value in change indicate a better health status. The higher the change from baseline, the better improvement
| units on a scale | ABX464 Treatment Arm |
|---|---|
| SF-36 Quality of Life Questionnaire (SF-36 Mental Component) | 6.38 ± 3.40 |
The change from Day 0 up to Month 48 in ESR levels
| mm/hour | ABX464 Treatment Arm |
|---|---|
| Erythrocyte Sedimentation Rate (ESR) Levels | 2.90 ± 8.62 |
Proportion of subjects with UC worsening based on adverse events
| Participants | ABX464 Treatment Arm |
|---|---|
| UC Worsening | 7 |
Collected over Adverse event were collected from first day of dosing (baseline) up to last safety visit (up to 49 months : 48 months on treatment and one month safety follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABX464 Treatment Arm | 0/22 (0%) | 3/22 (13.6%) | 20/22 (90.9%) |
| Event | ABX464 Treatment Arm |
|---|---|
| Myocardial infarctionCardiac disorders | 1/22 |
| enteropathic spondylitisMusculoskeletal and connective tissue disorders | 1/22 |
| benign ovarian tumorNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/22 |
| Event | ABX464 Treatment Arm |
|---|---|
| colitis ulcerativeGastrointestinal disorders | 7/22 |
| Abdominal painGastrointestinal disorders | 5/22 |
| nasopharyngitisInfections and infestations | 5/22 |
| diarrhoeaGastrointestinal disorders | 4/22 |
| vomitingGastrointestinal disorders | 3/22 |
| headacheNervous system disorders | 3/22 |
| Abdominal pain upperGastrointestinal disorders | 2/22 |
| DyspepsiaGastrointestinal disorders | 2/22 |
| nauseaGastrointestinal disorders | 2/22 |
| PyrexiaGeneral disorders | 2/22 |
| Age, Continuous(years) | ABX464 Treatment Arm |
|---|---|
| Mean | 42.4 ± 14.3 |
| Sex: Female, Male(Participants) | ABX464 Treatment Arm |
|---|---|
| Female | 9 |
| Male | 13 |
| Race (NIH/OMB)(Participants) | ABX464 Treatment Arm |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 22 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | ABX464 Treatment Arm |
|---|---|
| Belgium | 3 |
| Poland | 10 |
| Hungary | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2018 to primary completion in Jul 2022, 53 months.
Results were first posted in Mar 2025, 2 years 7 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 53 months is above that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464